Re-2 Papaverine recalls
The FDA has published 1 recall involving Re-2 Papaverine since 2022. The latest was reported on 1 Jun 2022. Most were for sterility. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls1since 2022
Last 12 months0reported
Class I00% of total
Ongoing0latest 1 Jun 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 1 100%Class III 0 0%
Why re-2 papaverine is recalled
Companies
By year
All re-2 papaverine recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | RE-2 Papaverine 30 mg/mL Phentolamine 3 mg/mL Alprostadil recalled | Olympia Compounding Pharmacy | Sterility | Nationwide |
Should you stop taking Re-2 Papaverine?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.